PLYX · Polaryx Therapeutics, Inc.
$2.11
+0.02 (+0.96%)
At close · Aug 27
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These matters, along with the conditions described above, raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements were available to be issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$104.18M
Shares
49.85M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.11
Open$2.09
Day$2.04–2.16
Available close range$1.87–35.00
Avg vol 30d114K
Short int249K · 0.5% float · 2.6d
Short vol71%
DataFeb 2026–Aug 2026
Filing10-Q · Aug 13
The closing range uses available history since Feb 2, 2026; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−7%
below
RSI (14)
47
neutral
MACD trend
Negative
52-week position
1%
near low
Momentum
relative strength
1-month return
−2%
trailing
6-month return
−23%
trailing
Relative strength
−38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
-7% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.50% of float · ▼ -3.0% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
13 holders — 13F breadth
Squeeze score
41
elevated · 0–100
Fundamentals
EPS growth
+78%
Y/Y
Balance sheet
$5.1M
net cash
Quant / Vol
risk profile
Volatility
219%
annualized · 1-yr
Max drawdown
−95%
past year
ATR
10.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−7%
Bearish
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
-7% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.50% of float · ▼ -3.0% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
13 holders — 13F breadth
Price context
position in its available closing range
Range low $2
Now $2 · 1%
Range high $35
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PLYX
this stock
Polaryx Therapeutics, Inc.
|
$104.18M | — | — | — | 0.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.8% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +4.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +25.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PLYX | -1.4% | -1.9% | -23.0% | -8.7% | — |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | -2.5% | -5.8% | -37.7% | -11.9% | — |
Key facts
CIK
2075320
CUSIP
73110F100
13F (30d)
12 filings
12 filers
Visit website
Investor relations